Premium
Complexes of anti‐prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces
Author(s) -
Simmelink Marleen J. A.,
Horbach Daniëlle A.,
Derksen Ronald H. W. M.,
Meijers Joost C. M.,
Bevers Edouard M.,
Willems George M.,
De Groot Philip G.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02755.x
Subject(s) - prothrombinase , lupus anticoagulant , chemistry , phospholipid , antibody , factor x , biochemistry , thrombin , microbiology and biotechnology , coagulation , biology , medicine , immunology , platelet , membrane
We investigated the mechanism by which anti‐prothrombin antibodies cause lupus anticoagulant (LAC) activity. Addition of affinity‐purified anti‐prothrombin antibodies from LAC‐positive plasma samples (α‐FII‐LAC + ) to normal plasma induced LAC activity. Upon increasing the phospholipid concentration, LAC activity was neutralized. Addition of purified α‐FII‐LAC + to normal plasma strongly inhibited factor Xa formation. No inhibition was measured when α‐FII‐LAC + were added to prothrombin‐deficient plasma or when purified anti‐prothrombin antibodies from LAC‐negative plasma samples (α‐FII‐LAC − ) were added. When a combination of prothrombin and α‐FII‐LAC + was added to the purified clotting complex, a strong inhibition of factor Xa and IIa formation was seen. The α‐FII‐LAC + alone or a combination of prothrombin and α‐FII‐LAC − did not show inhibition. Ellipsometry studies showed that, in the presence of α‐FII‐LAC + , the affinity of prothrombin for a phospholipid surface increased dramatically, whereas a much lower increase was observed with α‐FII‐LAC − . Our results show that complexes of prothrombin and anti‐prothrombin antibodies with LAC activity inhibit both prothrombinase and tenase. The antibodies increase the affinity of prothrombin for the phospholipid surface, thereby competing with clotting factors for the available catalytic phospholipid surface, a mechanism similar to that of anti‐β 2 ‐glycoprotein I antibodies.